<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">89</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:CCBBD2E1-BDAF-5702-AE4B-0E4910A4C7D6</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Pharmacia</journal-title>
        <abbrev-journal-title xml:lang="en">PHAR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0428-0296</issn>
      <issn pub-type="epub">2603-557X</issn>
      <publisher>
        <publisher-name>Bulgarian Pharmaceutical Scientific Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/pharmacia.70.e115795</article-id>
      <article-id pub-id-type="publisher-id">115795</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Relationship of serum Fetuin-A with metabolic and vascular parameters in patients with prediabetes and type 2 diabetes mellitus</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Karamfilova</surname>
            <given-names>Vera</given-names>
          </name>
          <email xlink:type="simple">verakaramfilova@abv.bg</email>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Nedeva</surname>
            <given-names>Iveta</given-names>
          </name>
          <email xlink:type="simple">iveta_nedeva@yahoo.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0002-8819-3032</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gatev</surname>
            <given-names>Tsvetan</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gateva</surname>
            <given-names>Antoaneta</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Assyov</surname>
            <given-names>Yavor</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gerganova</surname>
            <given-names>Antonina</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Popov</surname>
            <given-names>Dobrin</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Velikova</surname>
            <given-names>Tsvetelina</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-0593-1272</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kamenov</surname>
            <given-names>Zdravko</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line>Clinic of Endocrinology and Metabolic diseases, University Hospital “Alexandrovska”, Department of Internal Medicine, Medical University-Sofia, Sofia, Bulgaria</addr-line>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line>Medical University-Sofia, Bulgaria, Department of Epidemiology and hygiene, Sofia, Bulgaria</addr-line>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line>Department of Clinical Immunology, University Hospital “Lozenetz”, Sofia, Bulgaria</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding authors: Iveta Nedeva (<email xlink:type="simple">iveta_nedeva@yahoo.com</email>); Vera Karamfilova (<email xlink:type="simple">verakaramfilova@abv.bg</email>)</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>12</month>
        <year>2023</year>
      </pub-date>
      <volume>70</volume>
      <issue>4</issue>
      <fpage>1455</fpage>
      <lpage>1461</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/A153A07C-A17B-5CDA-ABA0-5CDB2F3CDFC8">A153A07C-A17B-5CDA-ABA0-5CDB2F3CDFC8</uri>
      <uri content-type="zenodo_dep_id" xlink:href="https://zenodo.org/record/0">0</uri>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>11</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Vera Karamfilova, Iveta Nedeva, Tsvetan Gatev, Antoaneta Gateva, Yavor Assyov, Antonina Gerganova, Dobrin Popov, Tsvetelina Velikova, Zdravko Kamenov</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p><bold>Background</bold>: Fetuin-A is a multifunctional liver-derived glycoprotein that is associated with insulin resistance and might play a role in the pathogenesis of prediabetes and type 2 diabetes (<abbrev xlink:title="type 2 diabetes" id="ABBRID0EUF">T2DM</abbrev>).</p>
        <p><bold>Objective</bold>: This study evaluated the relationship of Fetuin-A with metabolic and vascular parameters in patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0E3F">T2DM</abbrev>.</p>
        <p><bold>Materials and methods</bold>: total 120 obese patients were included. They were divided into three groups: group 1 – without carbohydrate disturbances, group 2 – with prediabetes and group 3 – with type 2 diabetes mellitus.</p>
        <p><bold>Results</bold>: Higher Fetuin-A serum levels were observed in patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EIG">T2DM</abbrev> compared to those with normoglycemia. Fetuin-A ≥821 mcg/ml increased the risk for <abbrev xlink:title="type 2 diabetes" id="ABBRID0EMG">T2DM</abbrev> 32-fold. Additionally, we found positive correlations between Fetuin-A, vibration perception threshold and toe-brachial index and a negative correlation with neuropathy disability score.</p>
        <p><bold>Conclusion</bold>: Fetuin-A could be predictive for incidents of prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EUG">T2DM</abbrev>.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>Fetuin-A</kwd>
        <kwd>prediabetes</kwd>
        <kwd>type 2 diabetes mellitus</kwd>
        <kwd>vascular parameters</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="SECID0E6G">
        <title>Citation</title>
        <p>Karamfilova V, Nedeva I, Gatev T, Gateva A, Assyov Y, Gerganova A, Popov D, Velikova T, Kamenov Z (2023) Relationship of serum Fetuin-A with metabolic and vascular parameters in patients with prediabetes and type 2 diabetes mellitus. Pharmacia 70(4): 1455–1461. <ext-link xlink:href="10.3897/pharmacia.70.e115795" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3897/pharmacia.70.e115795</ext-link></p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="SECID0EKH">
      <title>Introduction</title>
      <p>Type 2 Diabetes mellitus (<abbrev xlink:title="Type 2 Diabetes mellitus" id="ABBRID0EQH">T2DM</abbrev>) is a worldwide pandemic which can lead to damage and failure of different organs, especially the nerves, eyes, kidneys, heart, and blood vessel. Cardiovascular diseases (<abbrev xlink:title="Cardiovascular diseases" id="ABBRID0EUH">CVD</abbrev>) are the most common cause of mortality in diabetic patients, as they account for 52% of deaths in <abbrev xlink:title="type 2 diabetes" id="ABBRID0EYH">T2DM</abbrev> (<xref ref-type="bibr" rid="B16">Morrish et al. 2001</xref>). According to the 2019 International Diabetes Federation (<abbrev xlink:title="International Diabetes Federation" id="ABBRID0EBAAC">IDF</abbrev>) statistics, the global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), and it is expecting to rise up to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. One in two (50.1%) people living with diabetes are not diagnosed (<xref ref-type="bibr" rid="B19">Saeedi et al. 2019</xref>). Prediabetic states, characterized by impaired fasting glycaemia (<abbrev xlink:title="impaired fasting glycaemia" id="ABBRID0EJAAC">IFG</abbrev>) or impaired glucose tolerance (<abbrev xlink:title="impaired glucose tolerance" id="ABBRID0ENAAC">IGT</abbrev>), have also been shown to be associated with <abbrev xlink:title="Cardiovascular diseases" id="ABBRID0ERAAC">CVD</abbrev> morbidity and mortality as well as with a number of microvascular complications (<xref ref-type="bibr" rid="B5">Gerstein et al. 2005</xref>). The global prevalence of impaired glucose tolerance is estimated to be 7.5% (374 million) in 2019 and predicted to reach 8.0% (454 million) by 2030 and 8.6% (548 million) by 2045 (<xref ref-type="bibr" rid="B19">Saeedi et al. 2019</xref>) it is therefore important to have a better understanding of the pathophysiology, in order to identify new approach to tackle or prevent the development of micro- and macrovascular complications early on.</p>
      <p>Hepatokines, like liver-derived hormones, can regulate systemic energy metabolism and insulin sensitivity through integrated organ crosstalk and could be involved in the development of <abbrev xlink:title="type 2 diabetes" id="ABBRID0E6AAC">T2DM</abbrev> and prediabetes. Fetuin-A, also known as alpha-2-Heremans-Schmid glycoprotein (64 kDa), is produced mainly by the liver. In humans, the fetuin A gene is located on chromosome 3q27, which has been identified as a suspected locus for <abbrev xlink:title="type 2 diabetes" id="ABBRID0EDBAC">T2DM</abbrev> and metabolic syndrome (MetS) (<xref ref-type="bibr" rid="B14">Mori et al. 2006</xref>). Fetuin-A is a multifunctional hepatokine that is associated with obesity, insulin resistance and non-alcoholic fatty liver disease (<xref ref-type="bibr" rid="B23">Stefan et al. 2006</xref>; <xref ref-type="bibr" rid="B27">Yilmaz et al. 2010</xref>; <xref ref-type="bibr" rid="B6">Haukeland et al. 2012</xref>). It is also considered a biomarker for neurovegetative diseases, as well as an indicator of cardiovascular risk, endothelial dysfunction and subclinical atherosclerosis (<xref ref-type="bibr" rid="B15">Mori et al. 2012</xref>; <xref ref-type="bibr" rid="B4">Dogru et al. 2013</xref>). It has been suggested that Fetuin-A exacerbates insulin resistance by inhibiting the insulin receptor tyrosine kinase, reducing the adiponectin expression, and increasing the production of some inflammatory cytokines (<xref ref-type="bibr" rid="B7">Hennige et al. 2008</xref>). It inhibits phosphorylation of the insulin receptors in the liver and muscles which leads to an impairment of insulin signaling and development of insulin resistance (<xref ref-type="bibr" rid="B7">Hennige et al. 2008</xref>). These findings suggest that fetuin-A may play a critical role in the regulation of insulin sensitivity. Fetuin-A-knockout mice demonstrated improved insulin sensitivity and resistance to weight gain induced by high-fat diet, whereas treatment with fetuin-A exerted the opposite effects (Heenige et al. 2008) Human studies suggest that circulating fetuin-A levels were positively associated with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EHCAC">T2DM</abbrev> and MetS as its role in the pathogenesis of prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0ELCAC">T2DM</abbrev> has been discussed (<xref ref-type="bibr" rid="B10">Ix et al. 2006</xref>).</p>
      <p>The objective of this study was to investigate the relationship of fetuin-A with basic metabolic and micro- / macrovascular parameters in patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EVCAC">T2DM</abbrev>.</p>
    </sec>
    <sec sec-type="materials|methods" id="SECID0EZCAC">
      <title>Materials and methods</title>
      <p>A total of 120 obese patients (34 males, 86 females; mean age 53.4±9.3 years, from 45 to 74 years old) recruited in a tertiary University clinic of Endocrinology participated in the study. Subjects were included in the study if they had obesity (<abbrev xlink:title="body mass index" id="ABBRID0E6CAC">BMI</abbrev> ≥ 30 kg/m<sup>2</sup>). Criteria for exclusion were as follows: liver dysfunction (any of the hepatic enzymes &gt;3 times the upper limit of normal); chronic kidney disease (eGFR estimated by CKD-EPI calculation &lt;60 ml/min/1.73m<sup>2</sup>), heart failure or ischemic heart disease; any proven neoplastic disease. The subjects were divided into three groups. Group 1 included 40 patients without carbohydrate disturbances, group 2 was with prediabetes (n=40) and group 3 with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EHDAC">T2DM</abbrev> (n=40). For the purpose of this study, prediabetes was defined specifically as impaired glucose tolerance (<abbrev xlink:title="impaired glucose tolerance" id="ABBRID0ELDAC">IGT</abbrev>) and/or impaired fasting glycemia (<abbrev xlink:title="impaired fasting glycaemia" id="ABBRID0EPDAC">IFG</abbrev>). According to the American Diabetes Association (<abbrev xlink:title="American Diabetes Association" id="ABBRID0ETDAC">ADA</abbrev>), <abbrev xlink:title="impaired glucose tolerance" id="ABBRID0EXDAC">IGT</abbrev> is defined as a 2-hour plasma glucose value in the 75-gram oral glucose tolerance test (<abbrev xlink:title="oral glucose tolerance test" id="ABBRID0E2DAC">OGTT</abbrev>) from ≥140 mg/dL (≥7.8 mmol/L) to ≤199 mg/dL (≤11.0 mmol/L). <abbrev xlink:title="impaired fasting glycaemia" id="ABBRID0E6DAC">IFG</abbrev> is defined as a fasting plasma glucose from 100 mg/dL (≥5.6 mmol/L) to 125 mg/dL (≤6.9 mmol/L). <abbrev xlink:title="type 2 diabetes" id="ABBRID0EDEAC">T2DM</abbrev> was defined for the purpose of this study as fasting plasma glucose ≥ 7 mmol/L or 2-hour plasma glucose value during <abbrev xlink:title="oral glucose tolerance test" id="ABBRID0EHEAC">OGTT</abbrev> ≥ 11.1 mmol/L. The project was approved by the University ethics committee for clinical studies (Protocol KP-06N23/11/18.12.2018) and all included patients signed an informed consent for participation in the study. The following study methods were used: Anthropometric parameters as weight (kg), height (m), body mass index (<abbrev xlink:title="body mass index" id="ABBRID0ELEAC">BMI</abbrev>; kg/m<sup>2</sup>), waist and hip circumference (cm), arterial blood pressure (mmHg) were measured by a standard method. Waist-to-hip ratio (<abbrev xlink:title="Waist-to-hip ratio" id="ABBRID0EREAC">WHR</abbrev>) and waist-to-stature ratio (<abbrev xlink:title="waist-to-stature ratio" id="ABBRID0EVEAC">WSR</abbrev>) were calculated. Visceral adiposity index (<abbrev xlink:title="visceral adiposity index" id="ABBRID0EZEAC">VAI</abbrev>) was calculated using the established formula: <abbrev xlink:title="visceral adiposity index" id="ABBRID0E4EAC">VAI</abbrev> = [WC/(36.85+ (1.89 · <abbrev xlink:title="body mass index" id="ABBRID0EBFAC">BMI</abbrev>))] · [triglycerides (<abbrev xlink:title="triglycerides" id="ABBRID0EFFAC">TG</abbrev>)/0.81] · [1.52/high-density lipoproteins (<abbrev xlink:title="high-density lipoproteins" id="ABBRID0EJFAC">HDL</abbrev>)] for females and <abbrev xlink:title="visceral adiposity index" id="ABBRID0ENFAC">VAI</abbrev> = [(WC/(39.68+(1.88 ·<abbrev xlink:title="body mass index" id="ABBRID0ERFAC">BMI</abbrev>))] · (<abbrev xlink:title="triglycerides" id="ABBRID0EVFAC">TG</abbrev>/1.03) · (1.31/<abbrev xlink:title="high-density lipoproteins" id="ABBRID0EZFAC">HDL</abbrev>) for males. <abbrev xlink:title="visceral adiposity index" id="ABBRID0E4FAC">VAI</abbrev> was validated as a tool for assessment of cardiometabolic risk by means of magnetic resonance imaging and euglycemic hyperinsulinemic clamp (<xref ref-type="bibr" rid="B1">Amato et al. 2010</xref>). Percentage body fat (%) was measured by means of Body Impedance analysis (<abbrev xlink:title="Body Impedance analysis" id="ABBRID0EFGAC">BIA</abbrev>) with TANITA-TM TBF-215 GS Body Composition Analyzer in fasting state. A standard <abbrev xlink:title="oral glucose tolerance test" id="ABBRID0EJGAC">OGTT</abbrev> with measurement of glucose and insulin on 0 minute (glucose 0, insulin 0), 60 minutes (glucose 60, insulin 60), and 120 minutes (glucose120, insulin120) was performed. Homeostatic model assessment for IR (<abbrev xlink:title="Homeostatic model assessment for IR" id="ABBRID0ENGAC">HOMA-IR</abbrev>) was calculated using the following formula: <abbrev xlink:title="Homeostatic model assessment for IR" id="ABBRID0ERGAC">HOMA-IR</abbrev> = fasting plasma glucose (mmol/l)*fasting serum insulin (mIU/ml)/22.5. IR was defined as a value of <abbrev xlink:title="Homeostatic model assessment for IR" id="ABBRID0EVGAC">HOMA-IR</abbrev> &gt;2.5. Metabolic syndrome was diagnosed following the <abbrev xlink:title="International Diabetes Federation" id="ABBRID0EZGAC">IDF</abbrev> criteria (<xref ref-type="bibr" rid="B2">Alberti et al. 2009</xref>).</p>
      <p>To assess subclinical atherosclerosis and peripheral artery disease, we used the following noninvasive methods: (1) Intima-media thickness (<abbrev xlink:title="Intima-media thickness" id="ABBRID0EDHAC">IMT</abbrev>) measurement of the common carotid artery by Cardio Health Station (Panasonic Corporation, Osaka, Japan); (2) ankle-brachial index (<abbrev xlink:title="Ankle-brachial index" id="ABBRID0EHHAC">ABI</abbrev>, represents the ratio between the systolic blood pressure at the ankle and the upper arm) and toe-brachial index (<abbrev xlink:title="toe-brachial index" id="ABBRID0ELHAC">TBI</abbrev>) (<xref ref-type="bibr" rid="B25">Tehan et al. 2016</xref>). The <abbrev xlink:title="toe-brachial index" id="ABBRID0ETHAC">TBI</abbrev> is a ratio of the systolic toe pressure divided by the highest systolic brachial pressure. Systolic toe pressure can be measured by placing an appropriately sized occlusive pneumatic cuff (between 15 and 25 mm) around the base of the proximal first or second toe and a photoplethysmography (<abbrev xlink:title="photoplethysmography" id="ABBRID0EXHAC">PPG</abbrev>) probe affixed to the distal pulp of the toe with adhesive tape (<xref ref-type="bibr" rid="B25">Tehan et al. 2016</xref>). To detect distal small fiber neuropathy we measured sweat function (<abbrev xlink:title="autonomic neuropathy risk" id="ABBRID0E6HAC">ANR</abbrev> - autonomic neuropathy risk), using Sudoscan TM (Impeto Medical, Paris, France) (<xref ref-type="bibr" rid="B12">Mao et al. 2017</xref>). We also evaluated peripheral somatic sensory neuropathy by using vibration perception threshold (<abbrev xlink:title="vibration perception threshold" id="ABBRID0EHIAC">VPT</abbrev>) assessed with a biothesiometer (<xref ref-type="bibr" rid="B12">Mao et al. 2017</xref>). Neuropathic deficits in the feet were determined using the neuropathy disability score (<abbrev xlink:title="neuropathy disability score" id="ABBRID0EPIAC">NDS</abbrev>), derived from inability to detect pinprick sensation (using Neurotip), vibration (using 128-Hz tuning fork), and differences in temperature sensation (using warm and cool rods) plus Achilles reflex (using tendon hammer) (<xref ref-type="bibr" rid="B3">Dasgupta et al. 2010</xref>).</p>
      <p>Measurement of serum Fetuin-A levels was performed by enzyme-linked immunosorbent assay (BioVender Laboratory Medicine, Brno, Czech Republic).</p>
      <p>For statistical analysis, the data were processed using the statistical package IBM SPSS Statistics version 25.0. Data are presented as mean ± SD. The following statistical methods were applied: variation, descriptive and graphic analyses; Kolmogorov-Smirnov’s and Shapiro-Wilk tests; analysis of variance for two independent samples; Mann-Whitney’s nonparametric test for two independent samples; correlation analysis and receiver operating characteristic (<abbrev xlink:title="receiver operating characteristic" id="ABBRID0E1IAC">ROC</abbrev>) curve analysis. The level of significance for rejecting the null hypothesis was p &lt; 0.05.</p>
    </sec>
    <sec sec-type="Results" id="SECID0E5IAC">
      <title>Results</title>
      <p>The clinical and biochemical characteristics of the patients divided by groups are shown in Tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>. The three groups did not differ with regards to age and main anthropometric parameters, excluding <abbrev xlink:title="visceral adiposity index" id="ABBRID0EMJAC">VAI</abbrev>, for which we observed significantly higher values in patients with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EQJAC">T2DM</abbrev>. Using correlation analysis, Fetuin-A correlated positively with weight (r=0.330; p &lt; 0.001), <abbrev xlink:title="body mass index" id="ABBRID0EUJAC">BMI</abbrev> (r=0.283; p=0.002), waist (r=0.341; p=0.001), glucose 0 min (r=0.285; p=0.025), glucose 60 min (r=0.283; p=0.007), insulin 0 min (r=0.279; p = 0.008), insulin 60 min (r=0.379; p&lt;0.001), insulin 120 min (r=0.397; p&lt;0.001) of <abbrev xlink:title="oral glucose tolerance test" id="ABBRID0EYJAC">OGTT</abbrev>, <abbrev xlink:title="aspartate aminotransferase" id="ABBRID0E3JAC">AST</abbrev> (r=0.280; p=0.004) and <abbrev xlink:title="alanine aminotransferase" id="ABBRID0EAKAC">ALT</abbrev> (r=0.336; p&lt;0.01). In patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EEKAC">T2DM</abbrev> Fetuin-A serum levels were higher compared to those with normoglycemia (933.8±366.7; 909.1±302.9 vs 621.3±95.0 mcg/ml, р &lt;0,05) (Fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
      <fig id="F1" position="float" orientation="portrait">
        <object-id content-type="doi">10.3897/pharmacia.70.e115795.figure1</object-id>
        <object-id content-type="arpha">937B8448-6729-5F56-8313-2F01D9BE5CD7</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Levels of Fetuin-A between the groups. *p &lt; 0.001.</p>
        </caption>
        <graphic xlink:href="pharmacia-70-e115795-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_947320.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/947320</uri>
        </graphic>
      </fig>
      <table-wrap id="T1" position="float" orientation="portrait">
        <label>Table 1.</label>
        <caption>
          <p>Comparative analysis between the groups according to age and anthropometric parameters.</p>
        </caption>
        <table id="TID0EZRAG" rules="all">
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Parameters</th>
              <th rowspan="1" colspan="1">Group 1 Obesity</th>
              <th rowspan="1" colspan="1">Group 2 Prediabetes</th>
              <th rowspan="1" colspan="1">Group 3 Type2 Diabetes</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age (years)</td>
              <td rowspan="1" colspan="1">53.7±7.9</td>
              <td rowspan="1" colspan="1">51.9±10.3</td>
              <td rowspan="1" colspan="1">54.6±9.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Weight (kg)</td>
              <td rowspan="1" colspan="1">93.6±11.1</td>
              <td rowspan="1" colspan="1">95.0±16.8</td>
              <td rowspan="1" colspan="1">100.9±28.3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="body mass index" id="ABBRID0EQMAC">BMI</abbrev> (kg/m<sup>2</sup>)</td>
              <td rowspan="1" colspan="1">35.2±3.5</td>
              <td rowspan="1" colspan="1">35.3±5.4</td>
              <td rowspan="1" colspan="1">34.8±8.7</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">% Fat mass</td>
              <td rowspan="1" colspan="1">40.3±7.2</td>
              <td rowspan="1" colspan="1">39.6±6.1</td>
              <td rowspan="1" colspan="1">35.9±8.9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="waist-to-hip ratio" id="ABBRID0ERNAC">WHR</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.89±0.09</td>
              <td rowspan="1" colspan="1">0.90±0.08</td>
              <td rowspan="1" colspan="1">0.95±0.09</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="waist-to-stature ratio" id="ABBRID0EDOAC">WSR</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.64±0.05</td>
              <td rowspan="1" colspan="1">0.66±0.08</td>
              <td rowspan="1" colspan="1">0.64±0.09</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="visceral adiposity index" id="ABBRID0EVOAC">VAI</abbrev>
              </td>
              <td rowspan="1" colspan="1">3.6±0.8</td>
              <td rowspan="1" colspan="1">4.6±1.3</td>
              <td rowspan="1" colspan="1"><bold>6.4±3.5</bold>*#</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>* p&lt;0,05 between groups 1 and 3; # p&lt;0,05 between groups 2 and 3; <abbrev xlink:title="body mass index" id="ABBRID0EJPAC">BMI</abbrev> - body mass index; <abbrev xlink:title="waist-to-hip ratio" id="ABBRID0ENPAC">WHR</abbrev> - waist-to-hip ratio; <abbrev xlink:title="waist-to-stature ratio" id="ABBRID0ERPAC">WSR</abbrev> - waist-to-stature ratio; <abbrev xlink:title="visceral adiposity index" id="ABBRID0EVPAC">VAI</abbrev> - visceral adiposity index.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T2" position="float" orientation="portrait">
        <label>Table 2.</label>
        <caption>
          <p>Comparative analysis of the studied parameters in the considered groups of patients.</p>
        </caption>
        <table id="TID0E5XAG" rules="all">
          <tbody>
            <tr>
              <th rowspan="2" colspan="1">Parameters</th>
              <th rowspan="1" colspan="3">Group 1 – obesity</th>
              <th rowspan="1" colspan="3">Group 2 – Prediabetes</th>
              <th rowspan="1" colspan="3">Group 3 – Type 2 Diabetes</th>
              <th rowspan="1" colspan="3">p</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">n</th>
              <th rowspan="1" colspan="1">X̄</th>
              <th rowspan="1" colspan="1">SD</th>
              <th rowspan="1" colspan="1">n</th>
              <th rowspan="1" colspan="1">X̄</th>
              <th rowspan="1" colspan="1">SD</th>
              <th rowspan="1" colspan="1">n</th>
              <th rowspan="1" colspan="1">X̄</th>
              <th rowspan="1" colspan="1">SD</th>
              <th rowspan="1" colspan="1">1–2</th>
              <th rowspan="1" colspan="1">1–3</th>
              <th rowspan="1" colspan="1">2–3</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="systolic blood pressure" id="ABBRID0EACAE">SBP</abbrev> (mmHg)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">128.55<sup>ac</sup></td>
              <td rowspan="1" colspan="1">19.81</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">124.87<sup>a</sup></td>
              <td rowspan="1" colspan="1">16.66</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">133.74<sup>bc</sup></td>
              <td rowspan="1" colspan="1">18.04</td>
              <td rowspan="1" colspan="1">0.473</td>
              <td rowspan="1" colspan="1">0.094</td>
              <td rowspan="1" colspan="1">
                <bold>0.022</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="diastolic blood pressure" id="ABBRID0EWDAE">DBP</abbrev> (mmHg)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">81.33<sup>a</sup></td>
              <td rowspan="1" colspan="1">11.47</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">80.69<sup>a</sup></td>
              <td rowspan="1" colspan="1">10.86</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">83.00<sup>a</sup></td>
              <td rowspan="1" colspan="1">8.90</td>
              <td rowspan="1" colspan="1">0.968</td>
              <td rowspan="1" colspan="1">0.395</td>
              <td rowspan="1" colspan="1">0.312</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="total cholesterol" id="ABBRID0EJFAE">TC</abbrev> (mmol/L)</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">5.58<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.43</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">5.61<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.16</td>
              <td rowspan="1" colspan="1">35</td>
              <td rowspan="1" colspan="1">5.42<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.48</td>
              <td rowspan="1" colspan="1">0.606</td>
              <td rowspan="1" colspan="1">0.478</td>
              <td rowspan="1" colspan="1">0.258</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="high density lipoproteins" id="ABBRID0E3GAE">HDL</abbrev> (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">1.42<sup>a</sup></td>
              <td rowspan="1" colspan="1">0.28</td>
              <td rowspan="1" colspan="1">37</td>
              <td rowspan="1" colspan="1">1.24<sup>b</sup></td>
              <td rowspan="1" colspan="1">0.34</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">1.07<sup>c</sup></td>
              <td rowspan="1" colspan="1">0.34</td>
              <td rowspan="1" colspan="1">
                <bold>0.010</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.044</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="low density lipoproteins" id="ABBRID0EYIAE">LDL</abbrev> (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">3.52<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.25</td>
              <td rowspan="1" colspan="1">37</td>
              <td rowspan="1" colspan="1">3.40<sup>ac</sup></td>
              <td rowspan="1" colspan="1">1.11</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">2.94<sup>bc</sup></td>
              <td rowspan="1" colspan="1">1.09</td>
              <td rowspan="1" colspan="1">0.899</td>
              <td rowspan="1" colspan="1">
                <bold>0.047</bold>
              </td>
              <td rowspan="1" colspan="1">0.078</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">VLDL (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">0.63<sup>a</sup></td>
              <td rowspan="1" colspan="1">0.31</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">1.00<sup>b</sup></td>
              <td rowspan="1" colspan="1">0.57</td>
              <td rowspan="1" colspan="1">37</td>
              <td rowspan="1" colspan="1">1.48<sup>b</sup></td>
              <td rowspan="1" colspan="1">1.22</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">0.127</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="triglycerides" id="ABBRID0ECMAE">TG</abbrev> (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">1.38<sup>a</sup></td>
              <td rowspan="1" colspan="1">0.68</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">2.14<sup>b</sup></td>
              <td rowspan="1" colspan="1">1.24</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">3.22<sup>b</sup></td>
              <td rowspan="1" colspan="1">2.65</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">0.091</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="aspartate aminotransferase" id="ABBRID0E2NAE">AST</abbrev> (U/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">18,.83<sup>a</sup></td>
              <td rowspan="1" colspan="1">8.38</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">21.21<sup>b</sup></td>
              <td rowspan="1" colspan="1">6.84</td>
              <td rowspan="1" colspan="1">34</td>
              <td rowspan="1" colspan="1">36.03<sup>b</sup></td>
              <td rowspan="1" colspan="1">29.07</td>
              <td rowspan="1" colspan="1">
                <bold>0.014</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.007</bold>
              </td>
              <td rowspan="1" colspan="1">0.093</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="alanine aminotransferase" id="ABBRID0EUPAE">ALT</abbrev> (U/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">21,35<sup>a</sup></td>
              <td rowspan="1" colspan="1">10.36</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">27.87<sup>b</sup></td>
              <td rowspan="1" colspan="1">16.51</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">42.95<sup>b</sup></td>
              <td rowspan="1" colspan="1">33.13</td>
              <td rowspan="1" colspan="1">
                <bold>0.041</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.003</bold>
              </td>
              <td rowspan="1" colspan="1">0.102</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="gamma glutamyl transpeptidase" id="ABBRID0ENRAE">GGT</abbrev> (U/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">33.20<sup>a</sup></td>
              <td rowspan="1" colspan="1">36.60</td>
              <td rowspan="1" colspan="1">37</td>
              <td rowspan="1" colspan="1">42.24<sup>b</sup></td>
              <td rowspan="1" colspan="1">32.30</td>
              <td rowspan="1" colspan="1">35</td>
              <td rowspan="1" colspan="1">93.89<sup>c</sup></td>
              <td rowspan="1" colspan="1">125.23</td>
              <td rowspan="1" colspan="1">
                <bold>0.044</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.010</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Creatinine (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">69.65<sup>a</sup></td>
              <td rowspan="1" colspan="1">12.92</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">73.77<sup>a</sup></td>
              <td rowspan="1" colspan="1">13.60</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">77.87<sup>a</sup></td>
              <td rowspan="1" colspan="1">20.14</td>
              <td rowspan="1" colspan="1">0,172</td>
              <td rowspan="1" colspan="1">0.094</td>
              <td rowspan="1" colspan="1">0.576</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><abbrev xlink:title="glucose at the zero minute" id="ABBRID0EXUAE">Glu 0</abbrev> (mmol/L)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">5.39<sup>a</sup></td>
              <td rowspan="1" colspan="1">0.44</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">6.16<sup>b</sup></td>
              <td rowspan="1" colspan="1">0.50</td>
              <td rowspan="1" colspan="1">31</td>
              <td rowspan="1" colspan="1">11.03<sup>c</sup></td>
              <td rowspan="1" colspan="1">5.02</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.021</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glu 60 (mmol/L)</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">7.87<sup>a</sup></td>
              <td rowspan="1" colspan="1">2.01</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">10.89<sup>b</sup></td>
              <td rowspan="1" colspan="1">2.77</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">13.01<sup>c</sup></td>
              <td rowspan="1" colspan="1">4.52</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.008</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glu 120 (mmol/L)</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">5.86<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.19</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">7.74<sup>b</sup></td>
              <td rowspan="1" colspan="1">1.64</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">10.86<sup>c</sup></td>
              <td rowspan="1" colspan="1">3.75</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.007</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Insulin 0 (mU/mL)</td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">12.80<sup>a</sup></td>
              <td rowspan="1" colspan="1">5.60</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">20.75<sup>b</sup></td>
              <td rowspan="1" colspan="1">11.61</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">34.25<sup>b</sup></td>
              <td rowspan="1" colspan="1">23.70</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">0.056</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Insulin 60 (mU/mL)</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">87.45<sup>a</sup></td>
              <td rowspan="1" colspan="1">54.27</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">146.53<sup>b</sup></td>
              <td rowspan="1" colspan="1">90.00</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">171.84<sup>b</sup></td>
              <td rowspan="1" colspan="1">119.42</td>
              <td rowspan="1" colspan="1">
                <bold>0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.010</bold>
              </td>
              <td rowspan="1" colspan="1">0.684</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Insulin 120 (mU/m)</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">47.37<sup>a</sup></td>
              <td rowspan="1" colspan="1">28.69</td>
              <td rowspan="1" colspan="1">37</td>
              <td rowspan="1" colspan="1">121.74<sup>b</sup></td>
              <td rowspan="1" colspan="1">83.48</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">136.40<sup>b</sup></td>
              <td rowspan="1" colspan="1">112.31</td>
              <td rowspan="1" colspan="1">
                <bold>0.026</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.002</bold>
              </td>
              <td rowspan="1" colspan="1">0.741</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="homeostatic model assessment of insulin resistance" id="ABBRID0E45AE">HOMA-IR</abbrev>
              </td>
              <td rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">3.10<sup>a</sup></td>
              <td rowspan="1" colspan="1">1.48</td>
              <td rowspan="1" colspan="1">32</td>
              <td rowspan="1" colspan="1">5.67<sup>b</sup></td>
              <td rowspan="1" colspan="1">3.26</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">11.85<sup>b</sup></td>
              <td rowspan="1" colspan="1">10.68</td>
              <td rowspan="1" colspan="1">
                <bold>&lt;0.001</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>0.029</bold>
              </td>
              <td rowspan="1" colspan="1">0.105</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>* same letters horizontally mean no significant difference; different letters - the presence of such (p&lt;0.05); <abbrev xlink:title="systolic blood pressure" id="ABBRID0EWAAG">SBP</abbrev>, systolic blood pressure; <abbrev xlink:title="diastolic blood pressure" id="ABBRID0E1AAG">DBP</abbrev>, diastolic blood pressure; <abbrev xlink:title="total cholesterol" id="ABBRID0E5AAG">TC</abbrev>, total cholesterol; <abbrev xlink:title="high density lipoproteins" id="ABBRID0ECBAG">HDL</abbrev>, high density lipoproteins; <abbrev xlink:title="low density lipoproteins" id="ABBRID0EGBAG">LDL</abbrev>, low density lipoproteins; <abbrev xlink:title="triglycerides" id="ABBRID0EKBAG">TG</abbrev>,triglycerides; <abbrev xlink:title="aspartate aminotransferase" id="ABBRID0EOBAG">AST</abbrev>, aspartate aminotransferase; <abbrev xlink:title="alanine aminotransferase" id="ABBRID0ESBAG">ALT</abbrev>, alanine aminotransferase; <abbrev xlink:title="gamma glutamyl transpeptidase" id="ABBRID0EWBAG">GGT</abbrev>, gamma glutamyl transpeptidase; <abbrev xlink:title="glucose at the zero minute" id="ABBRID0E1BAG">Glu 0</abbrev>, glucose at the zero minute; <abbrev xlink:title="glucose at the sixties minutes" id="ABBRID0E5BAG">Glu60</abbrev>: glucose at the sixties minutes; <abbrev xlink:title="glucose at the one hundred and twenty minutes" id="ABBRID0ECCAG">Glu120</abbrev>: glucose at the one hundred and twenty minutes; <abbrev xlink:title="insulin at the zero minute" id="ABBRID0EGCAG">Insulin0</abbrev>: insulin at the zero minute; <abbrev xlink:title="insulin at the sixties minutes" id="ABBRID0EKCAG">Insulin60</abbrev>: insulin at the sixties minutes; <abbrev xlink:title="insulin at the one hundred and twenty minutes" id="ABBRID0EOCAG">Insulin120</abbrev>: insulin at the one hundred and twenty minutes; <abbrev xlink:title="homeostatic model assessment of insulin resistance" id="ABBRID0ESCAG">HOMA-IR</abbrev>: homeostatic model assessment of insulin resistance.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>A multiple binary logistic regression analysis was conducted to assess whether Fetuin-A has any predictive value for determination of risk for prediabetes, <abbrev xlink:title="type 2 diabetes" id="ABBRID0EYCAG">T2DM</abbrev> and MetS. The <abbrev xlink:title="receiver operating characteristic" id="ABBRID0E3CAG">ROC</abbrev> curves method was applied to find a threshold value (Figs <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref>). Fetuin-A levels ≥ 805 mcg/ml had the best discriminative value for differentiating patients with obesity and prediabetes (Table <xref ref-type="table" rid="T3">3</xref>). Patients with circulating serum Fetuin-A ≥805 mcg/ml had a 15-fold higher risk of prediabetes (Table <xref ref-type="table" rid="T4">4</xref>). Fetuin-A ≥ 821 mcg/ml had the best value to differentiate subject with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EQDAG">T2DM</abbrev> (Table <xref ref-type="table" rid="T5">5</xref>). Fetuin-A levels ≥821 mcg/ml increased the risk for <abbrev xlink:title="type 2 diabetes" id="ABBRID0EYDAG">T2DM</abbrev> approximately 32 times (OR 31.667, 95% CI 6.659–150.598, p &lt; 0.001). Fetuin-A values ≥824 mcg/ml differentiated subject with MetS (AUC=0.632, р=0.040, sensitivity of 42%, specificity 81% and precision 51%). Fetuin-A levels ≥824 mcg/ml were associated with a 4fold higher risk for MetS (OR 4.107, 95% CI 1.304–12.932, р=0.016).</p>
      <fig id="F2" position="float" orientation="portrait">
        <object-id content-type="doi">10.3897/pharmacia.70.e115795.figure2</object-id>
        <object-id content-type="arpha">7CED591E-6062-593A-819D-BB68A7CACB4F</object-id>
        <label>Figure 2.</label>
        <caption>
          <p><abbrev xlink:title="receiver operating characteristic" id="ABBRID0EEEAG">ROC</abbrev> curve of Fetuin-A (AUC=0.756, p&lt;0.001) to determine а threshold value for differentiation between patients with obesity and prediabetes.</p>
        </caption>
        <graphic xlink:href="pharmacia-70-e115795-g002.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_947321.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/947321</uri>
        </graphic>
      </fig>
      <fig id="F3" position="float" orientation="portrait">
        <object-id content-type="doi">10.3897/pharmacia.70.e115795.figure3</object-id>
        <object-id content-type="arpha">9A48D96E-54F9-59FC-BA21-3ABAFE119439</object-id>
        <label>Figure 3.</label>
        <caption>
          <p><abbrev xlink:title="receiver operating characteristic" id="ABBRID0EVEAG">ROC</abbrev> curve of Fetuin-A (AUC=0.807, р &lt; 0.001) to determine а threshold value for differentiation between patients with obesity and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EZEAG">T2DM</abbrev>.</p>
        </caption>
        <graphic xlink:href="pharmacia-70-e115795-g003.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_947322.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/947322</uri>
        </graphic>
      </fig>
      <table-wrap id="T3" position="float" orientation="portrait">
        <label>Table 3.</label>
        <caption>
          <p>Threshold levels of Fetuin-A and criteria for validation when differentiating patients with and without prediabetes and values of the criteria for validation of screening tests.</p>
        </caption>
        <table id="TID0EDEAI" rules="all">
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Parameter</th>
              <th rowspan="1" colspan="1">Threshold value</th>
              <th rowspan="1" colspan="1">Sensitivity</th>
              <th rowspan="1" colspan="1">Specificity</th>
              <th rowspan="1" colspan="1">Positive predictive value (%)</th>
              <th rowspan="1" colspan="1">Negative predictive value (%)</th>
              <th rowspan="1" colspan="1">Precision(%)</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fetuin- A</td>
              <td rowspan="1" colspan="1">≥805</td>
              <td rowspan="1" colspan="1">55</td>
              <td rowspan="1" colspan="1">93</td>
              <td rowspan="1" colspan="1">88</td>
              <td rowspan="1" colspan="1">67</td>
              <td rowspan="1" colspan="1">74</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T4" position="float" orientation="portrait">
        <label>Table 4.</label>
        <caption>
          <p>Odds ratio and 95% confidence intervals of the studied predictors for development of prediabetes.</p>
        </caption>
        <table id="TID0EHHAI" rules="all">
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Parameter</th>
              <th rowspan="1" colspan="1">Comparison</th>
              <th rowspan="1" colspan="1">OR</th>
              <th rowspan="1" colspan="1">Lower limit</th>
              <th rowspan="1" colspan="1">Upper limit</th>
              <th rowspan="1" colspan="1">Р value</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fetuin- A</td>
              <td rowspan="1" colspan="1">≥ 805 / &lt; 805</td>
              <td rowspan="1" colspan="1">15.074</td>
              <td rowspan="1" colspan="1">3.982</td>
              <td rowspan="1" colspan="1">57.069</td>
              <td rowspan="1" colspan="1">&lt; 0.001</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T5" position="float" orientation="portrait">
        <label>Table 5.</label>
        <caption>
          <p>Threshold levels of Fetuin-A and criteria for validation when differentiating patients with and without <abbrev xlink:title="type 2 diabetes" id="ABBRID0EVIAG">T2DM</abbrev> and values of the criteria for validation of screening tests.</p>
        </caption>
        <table id="TID0EBKAI" rules="all">
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Parameter</th>
              <th rowspan="1" colspan="1">Threshold value</th>
              <th rowspan="1" colspan="1">Sensitivity</th>
              <th rowspan="1" colspan="1">Specificity</th>
              <th rowspan="1" colspan="1">Positive predictive value (%)</th>
              <th rowspan="1" colspan="1">Negative predictive value (%)</th>
              <th rowspan="1" colspan="1">Precision(%)</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fetuin- A</td>
              <td rowspan="1" colspan="1">≥ 821</td>
              <td rowspan="1" colspan="1">63</td>
              <td rowspan="1" colspan="1">95</td>
              <td rowspan="1" colspan="1">93</td>
              <td rowspan="1" colspan="1">72</td>
              <td rowspan="1" colspan="1">79</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>From the studied parameters for micro- and macrovascular risk, we found positive correlations of Fetuin-A with vibration perception threshold and toe-brachial index, as well as a negative correlation with neuropathy disability score (Table <xref ref-type="table" rid="T6">6</xref>). There was no correlation of Fetuin-A with ankle-brachial index, intima-media thickness and autonomic neuropathy risk.</p>
      <table-wrap id="T6" position="float" orientation="portrait">
        <label>Table 6.</label>
        <caption>
          <p>Correlation analysis between micro- / macrovascular parameters and Fetuin-A.</p>
        </caption>
        <table id="TID0EHNAI" rules="all">
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Parameters</th>
              <th rowspan="1" colspan="1">Fetuin-A</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Ankle-brachial index" id="ABBRID0EHLAG">ABI</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.076</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Intima-media thickness" id="ABBRID0ETLAG">IMT</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.091</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Vibration perception threshold" id="ABBRID0E6LAG">VPT</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.208<sup>*</sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Neuropathy disability score" id="ABBRID0ENMAG">NDS</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.300<sup>**</sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Autonomic neuropathy risk" id="ABBRID0E2MAG">ANR</abbrev>
              </td>
              <td rowspan="1" colspan="1">-0.118</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="Toebrachial index" id="ABBRID0EHNAG">TBI</abbrev>
              </td>
              <td rowspan="1" colspan="1">0.225<sup>*</sup></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>* - p &lt; 0.05, ** - p &lt; 0.01, *** - p &lt; 0.001 <abbrev xlink:title="Ankle-brachial index" id="ABBRID0EUNAG">ABI</abbrev> - Ankle-brachial index; <abbrev xlink:title="Intima-media thickness" id="ABBRID0EYNAG">IMT</abbrev> - Intima-media thickness; <abbrev xlink:title="Vibration perception threshold" id="ABBRID0E3NAG">VPT</abbrev> - Vibration perception threshold; <abbrev xlink:title="Neuropathy disability score" id="ABBRID0EAOAG">NDS</abbrev> - Neuropathy disability score; <abbrev xlink:title="Autonomic neuropathy risk" id="ABBRID0EEOAG">ANR</abbrev> - Autonomic neuropathy risk; <abbrev xlink:title="Toebrachial index" id="ABBRID0EIOAG">TBI</abbrev> - Toebrachial index.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="Discussion" id="SECID0EMOAG">
      <title>Discussion</title>
      <p>The results of this study have shown higher Fetuin-A levels in the patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0ESOAG">T2DM</abbrev> in comparison with those without any glycemic disorders. We have also demonstrated that Fetuin-A levels correlated positively with important micro- and macrovascular indicators. This is the first study that evaluates the association between serum Fetuin-A concentrations and the whole spectrum of the carbohydrate metabolism - through prediabetes and type 2 diabetes mellitus, and its relationship with important vascular parameters. Several studies reported that serum Fetuin-A concentrations are significantly higher in patients with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EWOAG">T2DM</abbrev> which is associated with its proposed mechanism of action leading to suppression of the insulin receptor tyrosine kinase (<xref ref-type="bibr" rid="B10">Ix et al. 2006</xref>). Although the effect of Fetuin-A on insulin sensitivity has been well established, little is known about the mechanisms regulating its expression. Two studies report that palmitate stimulates nuclear factor-κB binding to the Fetuin-A promoter in order to increase the expression of Fetuin-A. Also high glucose enhances Fetuin-A expression through activation of ERK1/2 (<xref ref-type="bibr" rid="B24">Takata et al. 2009</xref>; <xref ref-type="bibr" rid="B3">Dasgupta et al. 2010</xref>). Another study suggests the involvement of endoplasmic reticulum stress induced by high glucose and palmitate significantly increases the expression of Fetuin-A and further contributes to the development of insulin resistance in human hepatoma cell line (HepG2) and in diabetic mice with high-fat diet induced insulin resistant (<xref ref-type="bibr" rid="B17">Ou et al. 2012</xref>). Therefore, it is plausible that in the presence of insulin resistance, the secretion of Fetuin-A might be up-regulated indirectly by the increased circulating glucose and free fatty acids and this leads to further deterioration of insulin resistance by Fetuin-A (<xref ref-type="bibr" rid="B17">Ou et al. 2012</xref>). In an observational study with 3075 elderly individuals (aged between 70 and 79 years), the authors established an independent association of high circulating Fetuin-A levels with incident of diabetes (<xref ref-type="bibr" rid="B11">Ix et al. 2008</xref>). In animal studies with fetuin-A-null mice, the models were protected against insulin resistance and showed higher insulin receptor autophosphorylation and tyrosine kinase activity in skeletal muscle and liver compared to wild-type mice (<xref ref-type="bibr" rid="B13">Mathews et al. 2006</xref>; <xref ref-type="bibr" rid="B7">Hennige et al. 2008</xref>). Despite these convincing data, not all studies have found an association between Fetuin-A and insulin resistance among established type 2 diabetic patients as some of the data are quite contradictory (<xref ref-type="bibr" rid="B14">Mori et al. 2006</xref>) do not establish statistically significant differences of Fetuin-A levels between nondiabetic and type 2 diabetic subjects. Serum Fetuin-A levels were significantly correlated with log(HOMA) in nondiabetic individuals (r=0.197, p =0.014) (<xref ref-type="bibr" rid="B14">Mori et al. 2006</xref>). In the same study the authors demonstrated the independent impact of Fetuin-A on insulin resistance in nondiabetic subjects. In human studies, serum Fetuin-A levels were associated with various types of metabolic complications. Fetuin-A levels correlated positively with <abbrev xlink:title="body mass index" id="ABBRID0ECQAG">BMI</abbrev>, visceral fat and waist circumference, as demonstrated by two previous cross-sectional studies (<xref ref-type="bibr" rid="B24">Takata et al. 2009</xref>). In addition, higher Fetuin-A levels are predictive for MetS and insulin resistance in nondiabetic, prediabetic and diabetic subjects (<xref ref-type="bibr" rid="B11">Ix et al. 2008</xref>; <xref ref-type="bibr" rid="B9">Ishibashi et al. 2010</xref>).</p>
      <p>In our study, where all patients were obese, we also found positive associations of Fetuin-A levels with weight, waist circumference and <abbrev xlink:title="body mass index" id="ABBRID0EUQAG">BMI</abbrev>, as well as with some main metabolic indicators including blood glucose, insulin, <abbrev xlink:title="Homeostatic model assessment for IR" id="ABBRID0EYQAG">HOMA-IR</abbrev>, <abbrev xlink:title="aspartate aminotransferase" id="ABBRID0E3QAG">AST</abbrev>, <abbrev xlink:title="alanine aminotransferase" id="ABBRID0EARAG">ALT</abbrev>. Moreover, we established that higher Fetuin-A was predictive for <abbrev xlink:title="type 2 diabetes" id="ABBRID0EERAG">T2DM</abbrev> and prediabetes.</p>
      <p>It is well established that <abbrev xlink:title="Cardiovascular diseases" id="ABBRID0EKRAG">CVD</abbrev> are the most common cause of mortality in diabetic patients, which accounts for 52% of deaths in <abbrev xlink:title="type 2 diabetes" id="ABBRID0EORAG">T2DM</abbrev> (<xref ref-type="bibr" rid="B16">Morrish et al. 2001</xref>). Patients with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EWRAG">T2DM</abbrev> are likely to have multiple atherosclerotic cardiovascular disease (<abbrev xlink:title="atherosclerotic cardiovascular disease" id="ABBRID0E1RAG">ASCVD</abbrev>) risk factors (including dyslipidemia and hypertension), each of which mediates an increase in risk of both <abbrev xlink:title="atherosclerotic cardiovascular disease" id="ABBRID0E5RAG">ASCVD</abbrev> and non-<abbrev xlink:title="atherosclerotic cardiovascular disease" id="ABBRID0ECSAG">ASCVD</abbrev>. Type 1 diabetes mellitus, <abbrev xlink:title="type 2 diabetes" id="ABBRID0EGSAG">T2DM</abbrev> and prediabetes are independent risk factors for <abbrev xlink:title="atherosclerotic cardiovascular disease" id="ABBRID0EKSAG">ASCVD</abbrev>, increasing its risk about two-fold, depending on the population and therapeutic control (<xref ref-type="bibr" rid="B20">Sarwar et al. 2010</xref>). Previous studies indicate a close bidirectional relationship between Fetuin-A and <abbrev xlink:title="Cardiovascular diseases" id="ABBRID0ESSAG">CVD</abbrev>. An association of Fetuin-A with the risk of myocardial infarction and ischemic stroke has been established, regardless of standard risk factors. It has not yet been decided whether Fetuin-A could be considered a potential biomarker of cardiovascular risk. In a case-cohort study, Weikert et al. showed that patients with higher Fetuin-A concentrations had 4-fold increased risk for myocardial infarction and ischemic stroke. Furthermore, a positive correlation of Fetuin-A with arterial stiffness and increased intima-media thickness have been observed in healthy subjects (<xref ref-type="bibr" rid="B26">Weikert et al. 2008</xref>). Many authors found that serum fetuin-A level may be a sensitive indicator for macrovascular complications in diabetic patients (<xref ref-type="bibr" rid="B21">Singh et al. 2012</xref>). On the other hand, some clinical studies have indicated the opposite trends- lower serum Fetuin-A levels have been associated with the presence of peripheral artery disease (<abbrev xlink:title="peripheral artery disease" id="ABBRID0E5SAG">PAD</abbrev>) in diabetics, increased arterial stiffness, atherosclerotic plaque calcification and progression of cardiovascular disease (Reinehr et al. 2008; <xref ref-type="bibr" rid="B28">Zhao et al. 2013</xref>). Hence, it is likely that both high and low Fetuin-A might cause cardiovascular dysfunction. This dual functionality of Fetuin-A needs further evaluation. Recent studies have revealed that long-term complications of diabetes could manifest even at the prediabetic state. The macrovascular disorders associated with prediabetes include <abbrev xlink:title="Cardiovascular diseases" id="ABBRID0EGTAG">CVD</abbrev>, stroke and peripheral arterial disease. In fact, the traditional <abbrev xlink:title="Cardiovascular diseases" id="ABBRID0EKTAG">CVD</abbrev> risk factors (dyslipidemia, obesity, hypertension) are quite prevalent among individuals with prediabetes (<xref ref-type="bibr" rid="B22">Stacey et al. 2015</xref>; <xref ref-type="bibr" rid="B8">Huang et al. 2016</xref>).</p>
      <p>Further we evaluated the relationship of Fetuin-A with some main macrovascular risk parameters in patients with obesity and/or prediabetes and/or <abbrev xlink:title="type 2 diabetes" id="ABBRID0EYTAG">T2DM</abbrev>, such as: ankle-brachial index, intima-media thickness and toe-brachial index. We found positive correlations between Fetuin-A, vibration perception threshold and toe-brachial index. The data in the literature on the relationship between Fetuin-A and microvascular risk factors in patient with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0E3TAG">T2DM</abbrev> is still insufficient. A meta-analysis reported pooled data on the association between circulating fetuin-A levels and all-cause mortality in patients with chronic kidney disease (CKD) (<xref ref-type="bibr" rid="B29">Zhou et al 2019</xref>). Data suggested that CKD patients with Fetuin-A levels in the lowest tertile had 92% greater risk of all-cause mortality compared to those in the highest tertile. In a subgroup analysis, the significant association between low Fetuin-A levels and higher risk of mortality was observed only among patients on dialysis. We also evaluated the relationship of Fetuin-A with some indicators of microangiopathy, including vibration perception threshold, neuropathy disability score and autonomic neuropathy risk. The results showed a positive correlation of Fetuin-A with vibration perception threshold and a negative correlation with neuropathy disability score. These findings suggest that even at the earliest stages of the glucose disturbances, Fetuin-A might play a key role in the development of the micro- and macrovascular complications, which are typical for people with <abbrev xlink:title="type 2 diabetes" id="ABBRID0EEUAG">T2DM</abbrev>.</p>
      <p>This study had several limitations. The sample size was relatively small and study design was cross-sectional. Additional longitudinal clinical studies with larger number of patients are needed to fully clarify its role. Important strengths of this study are that all subjects were with obesity and that patients with glucose disturbances did not receive any glucose-lowering medications.</p>
    </sec>
    <sec sec-type="Conclusion" id="SECID0EJUAG">
      <title>Conclusion</title>
      <p>Serum level of Fetuin-A was significantly higher in patients with carbohydrate disturbances and correlated with the basic anthropometric and metabolic parameters, as well as with markers for micro- and macroangiopathy. Fetuin-A could be predictive for incidents of prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0EPUAG">T2DM</abbrev>. Further studies are needed to fully evaluate the relationship of FetuinA with different vascular complications in patients with prediabetes and <abbrev xlink:title="type 2 diabetes" id="ABBRID0ETUAG">T2DM</abbrev>.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This study is financed by the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, project № BG-RRP-2.004-0004-C01.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Amato</surname><given-names>MC</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>C</given-names></name><name name-style="western"><surname>Galia</surname><given-names>M</given-names></name><name name-style="western"><surname>Criscimanna</surname><given-names>A</given-names></name><name name-style="western"><surname>Vitabile</surname><given-names>S</given-names></name><name name-style="western"><surname>Midiri</surname><given-names>M</given-names></name><name name-style="western"><surname>Galluzzo</surname><given-names>A</given-names></name></person-group> (<year>2010</year>) <article-title>AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.</article-title><source>Diabetes Care</source><volume>33</volume>(<issue>4</issue>): <fpage>920</fpage>–<lpage>922</lpage>. <ext-link xlink:href="10.2337/dc09-1825" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2337/dc09-1825</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Alberti</surname><given-names>KG</given-names></name><name name-style="western"><surname>Eckel</surname><given-names>RH</given-names></name><name name-style="western"><surname>Grundy</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zimmet</surname><given-names>PZ</given-names></name><name name-style="western"><surname>Cleeman</surname><given-names>JI</given-names></name><name name-style="western"><surname>Donato</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fruchart</surname><given-names>JC</given-names></name><name name-style="western"><surname>James</surname><given-names>WP</given-names></name><name name-style="western"><surname>Loria</surname><given-names>CM</given-names></name><name name-style="western"><surname>Smith Jr</surname><given-names>SC</given-names></name></person-group> (<year>2009</year>) <article-title>International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and PreventionNational Heart, Lung, and Blood Institute American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.</article-title><source>Circulation</source><volume>120</volume>(<issue>16</issue>): <fpage>1640</fpage>–<lpage>1645</lpage>. <ext-link xlink:href="10.1161/CIRCULATIONAHA.109.192644" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1161/CIRCULATIONAHA.109.192644</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Dasgupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>A</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>SS</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group> (<year>2010</year>) <article-title>NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance.</article-title><source>The Biochemical Journal</source><volume>429</volume>(<issue>3</issue>): <fpage>451</fpage>–<lpage>462</lpage>. <ext-link xlink:href="10.1042/BJ20100330" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1042/BJ20100330</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Dogru</surname><given-names>T</given-names></name><name name-style="western"><surname>Genc</surname><given-names>H</given-names></name><name name-style="western"><surname>Tapan</surname><given-names>S</given-names></name><name name-style="western"><surname>Aslan</surname><given-names>F</given-names></name><name name-style="western"><surname>Ercin</surname><given-names>CN</given-names></name><name name-style="western"><surname>Ors</surname><given-names>F</given-names></name><name name-style="western"><surname>Kara</surname><given-names>M</given-names></name><name name-style="western"><surname>Sertoglu</surname><given-names>E</given-names></name><name name-style="western"><surname>Karslioglu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bagci</surname><given-names>S</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>I</given-names></name><name name-style="western"><surname>Sonmez</surname><given-names>A</given-names></name></person-group> (<year>2013</year>) <article-title>Plasma Fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.</article-title><source>Clinical Endocrinology</source><volume>78</volume>(<issue>5</issue>): <fpage>712</fpage>–<lpage>717</lpage>. <ext-link xlink:href="10.1111/j.1365-2265.2012.04460.x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/j.1365-2265.2012.04460.x</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Gerstein</surname><given-names>HC</given-names></name><name name-style="western"><surname>Pogue</surname><given-names>J</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JF</given-names></name><name name-style="western"><surname>Lonn</surname><given-names>E</given-names></name><name name-style="western"><surname>Dagenais</surname><given-names>GR</given-names></name><name name-style="western"><surname>McQueen</surname><given-names>M</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name></person-group> (<year>2005</year>) <article-title>The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis.</article-title><source>Diabetologia</source><volume>48</volume>(<issue>9</issue>): <fpage>1749</fpage>–<lpage>1755</lpage>. <ext-link xlink:href="10.1007/s00125-005-1858-4" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/s00125-005-1858-4</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Haukeland</surname><given-names>JW</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>TB</given-names></name><name name-style="western"><surname>Yndestad</surname><given-names>A</given-names></name><name name-style="western"><surname>Gladhaug</surname><given-names>IP</given-names></name><name name-style="western"><surname>Løberg</surname><given-names>EM</given-names></name><name name-style="western"><surname>Haaland</surname><given-names>T</given-names></name><name name-style="western"><surname>Konopski</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wium</surname><given-names>C</given-names></name><name name-style="western"><surname>Aasheim</surname><given-names>ET</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>OE</given-names></name><name name-style="western"><surname>Aukrust</surname><given-names>P</given-names></name><name name-style="western"><surname>Halvorsen</surname><given-names>B</given-names></name><name name-style="western"><surname>Birkeland</surname><given-names>KI</given-names></name></person-group> (<year>2012</year>) <article-title>Fetuin-A in nonalcoholic fatty liver disease: In vivo and in vitro studies.</article-title><source>European Journal of Endocrinology</source><volume>166</volume>(<issue>3</issue>): <fpage>503</fpage>–<lpage>510</lpage>. <ext-link xlink:href="10.1530/EJE-11-0864" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1530/EJE-11-0864</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hennige</surname><given-names>AM</given-names></name><name name-style="western"><surname>Staiger</surname><given-names>H</given-names></name><name name-style="western"><surname>Wicke</surname><given-names>C</given-names></name><name name-style="western"><surname>Machicao</surname><given-names>F</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>A</given-names></name><name name-style="western"><surname>Häring</surname><given-names>HU</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>N</given-names></name></person-group> (<year>2008</year>) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3(3): e1765. <ext-link xlink:href="10.1371/journal.pone.0001765" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1371/journal.pone.0001765</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Mai</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name></person-group> (<year>2016</year>) Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ [Clinical Research Ed.] 355: i5953. <ext-link xlink:href="10.1136/bmj.i5953" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1136/bmj.i5953</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ishibashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohguro</surname><given-names>T</given-names></name><name name-style="western"><surname>Kumon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Takata</surname><given-names>H</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Suehiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y</given-names></name></person-group> (<year>2010</year>) <article-title>Serum Fetuin-A is an independent marker of insulin resistance in Japanese men.</article-title><source>Journal of Atherosclerosis and Thrombosis</source><volume>17</volume>(<issue>9</issue>): <fpage>925</fpage>–<lpage>933</lpage>. <ext-link xlink:href="10.5551/jat.3830" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5551/jat.3830</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ix</surname><given-names>JH</given-names></name><name name-style="western"><surname>Shlipak</surname><given-names>MG</given-names></name><name name-style="western"><surname>Brandenburg</surname><given-names>VM</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S</given-names></name><name name-style="western"><surname>Ketteler</surname><given-names>M</given-names></name><name name-style="western"><surname>Whooley</surname><given-names>MA</given-names></name></person-group> (<year>2006</year>) <article-title>Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study.</article-title><source>Circulation</source><volume>113</volume>(<issue>14</issue>): <fpage>1760</fpage>–<lpage>1767</lpage>. <ext-link xlink:href="10.1161/CIRCULATIONAHA.105.588723" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1161/CIRCULATIONAHA.105.588723</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ix</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wassel</surname><given-names>CL</given-names></name><name name-style="western"><surname>Kanaya</surname><given-names>AM</given-names></name><name name-style="western"><surname>Vittinghoff</surname><given-names>E</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KC</given-names></name><name name-style="western"><surname>Koster</surname><given-names>A</given-names></name><name name-style="western"><surname>Cauley</surname><given-names>JA</given-names></name><name name-style="western"><surname>Harris</surname><given-names>TB</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>SR</given-names></name><name name-style="western"><surname>Shlipak</surname><given-names>MG</given-names></name></person-group> (<year>2008</year>) <article-title>Fetuin-A and incident diabetes mellitus in older persons.</article-title><source>Journal of the American Medical Association</source><volume>300</volume>(<issue>2</issue>): <fpage>182</fpage>–<lpage>188</lpage>. <ext-link xlink:href="10.1001/jama.300.2.182" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1001/jama.300.2.182</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mao</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group> (<year>2017</year>) <article-title>Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in Chinese type 2 diabetes mellitus patients.</article-title><source>Journal of Diabetes Investigation</source><volume>8</volume>(<issue>3</issue>): <fpage>363</fpage>–<lpage>368</lpage>. <ext-link xlink:href="10.1111/jdi.12575" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/jdi.12575</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mathews</surname><given-names>ST</given-names></name><name name-style="western"><surname>Rakhade</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Parker</surname><given-names>GC</given-names></name><name name-style="western"><surname>Coscina</surname><given-names>DV</given-names></name><name name-style="western"><surname>Grunberger</surname><given-names>G</given-names></name></person-group> (<year>2006</year>) <article-title>Fetuin-null mice are protected against obesity and insulin resistance associated with aging.</article-title><source>Biochemical and Biophysical Research Communications</source><volume>350</volume>(<issue>2</issue>): <fpage>437</fpage>–<lpage>443</lpage>. <ext-link xlink:href="10.1016/j.bbrc.2006.09.071" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.bbrc.2006.09.071</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Emoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Araki</surname><given-names>T</given-names></name><name name-style="western"><surname>Teramura</surname><given-names>M</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>T</given-names></name><name name-style="western"><surname>Inaba</surname><given-names>M</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>Y</given-names></name></person-group> (<year>2006</year>) <article-title>Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects.</article-title><source>Diabetes Care</source><volume>29</volume>(<issue>2</issue>): <fpage>468</fpage>. <ext-link xlink:href="10.2337/diacare.29.02.06.dc05-1484" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2337/diacare.29.02.06.dc05-1484</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Emoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Inaba</surname><given-names>M</given-names></name></person-group> (<year>2012</year>) <article-title>Fetuin-A and the cardiovascular system.</article-title><source>Advances in Clinical Chemistry</source><volume>56</volume>: <fpage>175</fpage>–<lpage>195</lpage>. <ext-link xlink:href="10.1016/B978-0-12-394317-0.00010-8" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/B978-0-12-394317-0.00010-8</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Morrish</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>LK</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>JH</given-names></name><name name-style="western"><surname>Keen</surname><given-names>H</given-names></name></person-group> (<year>2001</year>) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(S2): S14–S21. <ext-link xlink:href="10.1007/PL00002934" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1007/PL00002934</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ou</surname><given-names>HY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>HT</given-names></name><name name-style="western"><surname>Hung</surname><given-names>HC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CJ</given-names></name></person-group> (<year>2012</year>) <article-title>Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance.</article-title><source>Endocrinology</source><volume>153</volume>(<issue>7</issue>): <fpage>2974</fpage>–<lpage>2984</lpage>. <ext-link xlink:href="10.1210/en.2011-2043" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1210/en.2011-2043</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Reinehr</surname><given-names>T</given-names></name><name name-style="western"><surname>Roth</surname><given-names>CL</given-names></name></person-group> (<year>2008</year>) <article-title>Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss.</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>93</volume>(<issue>11</issue>): <fpage>4479</fpage>–<lpage>4485</lpage>. <ext-link xlink:href="10.1210/jc.2008-1505" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1210/jc.2008-1505</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersohn</surname><given-names>I</given-names></name><name name-style="western"><surname>Salpea</surname><given-names>P</given-names></name><name name-style="western"><surname>Malanda</surname><given-names>B</given-names></name><name name-style="western"><surname>Karuranga</surname><given-names>S</given-names></name><name name-style="western"><surname>Unwin</surname><given-names>N</given-names></name><name name-style="western"><surname>Colagiuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Guariguata</surname><given-names>L</given-names></name><name name-style="western"><surname>Motala</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ogurtsova</surname><given-names>K</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bright</surname><given-names>D</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R</given-names></name></person-group> (<year>2019</year>) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9<sup>th</sup> edn. Diabetes Research and Clinical Practice 157: 107843. <ext-link xlink:href="10.1016/j.diabres.2019.107843" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.diabres.2019.107843</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sarwar</surname><given-names>N</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Seshasai</surname><given-names>SR</given-names></name><name name-style="western"><surname>Gobin</surname><given-names>R</given-names></name><name name-style="western"><surname>Kaptoge</surname><given-names>S</given-names></name><name name-style="western"><surname>Di Angelantonio</surname><given-names>E</given-names></name><name name-style="western"><surname>Ingelsson</surname><given-names>E</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>DA</given-names></name><name name-style="western"><surname>Selvin</surname><given-names>E</given-names></name><name name-style="western"><surname>Stampfer</surname><given-names>M</given-names></name><name name-style="western"><surname>Stehouwer</surname><given-names>CD</given-names></name><name name-style="western"><surname>Lewington</surname><given-names>S</given-names></name><name name-style="western"><surname>Pennells</surname><given-names>L</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>N</given-names></name><name name-style="western"><surname>White</surname><given-names>IR</given-names></name><name name-style="western"><surname>Ray</surname><given-names>KK</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>J</given-names></name></person-group> (<year>2010</year>) <article-title>The emerging risk factors collaboration diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies.</article-title><source>Lancet</source><volume>375</volume>(<issue>9733</issue>): <fpage>2215</fpage>–<lpage>2222</lpage>. <ext-link xlink:href="10.1016/S0140-6736(10)60484-9" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/S0140-6736(10)60484-9</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>PK</given-names></name><name name-style="western"><surname>Garg</surname><given-names>VK</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>SC</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name></person-group> (<year>2012</year>) <article-title>Role of fetuin-A in atherosclerosis associated with diabetic patients.</article-title><source>The Journal of Pharmacy and Pharmacology</source><volume>64</volume>(<issue>12</issue>): <fpage>1703</fpage>–<lpage>1708</lpage>. <ext-link xlink:href="10.1111/j.2042-7158.2012.01561.x" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1111/j.2042-7158.2012.01561.x</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Stacey</surname><given-names>RB</given-names></name><name name-style="western"><surname>Leaverton</surname><given-names>PE</given-names></name><name name-style="western"><surname>Schocken</surname><given-names>DD</given-names></name><name name-style="western"><surname>Peregoy</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bertoni</surname><given-names>AG</given-names></name></person-group> (<year>2015</year>) <article-title>Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis.</article-title><source>American Heart Journal</source><volume>170</volume>(<issue>5</issue>): <fpage>923</fpage>–<lpage>928</lpage>. <ext-link xlink:href="10.1016/j.ahj.2015.08.003" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1016/j.ahj.2015.08.003</ext-link></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Stefan</surname><given-names>N</given-names></name><name name-style="western"><surname>Hennige</surname><given-names>AM</given-names></name><name name-style="western"><surname>Staiger</surname><given-names>H</given-names></name><name name-style="western"><surname>Machann</surname><given-names>J</given-names></name><name name-style="western"><surname>Schick</surname><given-names>F</given-names></name><name name-style="western"><surname>Kröber</surname><given-names>SM</given-names></name><name name-style="western"><surname>Machicao</surname><given-names>F</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>A</given-names></name><name name-style="western"><surname>Häring</surname><given-names>HU</given-names></name></person-group> (<year>2006</year>) <article-title>Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.</article-title><source>Diabetes Care</source><volume>29</volume>(<issue>4</issue>): <fpage>853</fpage>–<lpage>857</lpage>. <ext-link xlink:href="10.2337/diacare.29.04.06.dc05-1938" ext-link-type="doi" xlink:type="simple">https://doi.org/10.2337/diacare.29.04.06.dc05-1938</ext-link></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Takata</surname><given-names>H</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suehiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y</given-names></name></person-group> (<year>2009</year>) <article-title>High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2 signaling pathway.</article-title><source>Journal of Atherosclerosis and Thrombosis</source><volume>16</volume>(<issue>4</issue>): <fpage>448</fpage>–<lpage>456</lpage>. <ext-link xlink:href="10.5551/jat.No950" ext-link-type="doi" xlink:type="simple">https://doi.org/10.5551/jat.No950</ext-link></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Tehan</surname><given-names>PE</given-names></name><name name-style="western"><surname>Santos</surname><given-names>D</given-names></name><name name-style="western"><surname>Chuter</surname><given-names>VH</given-names></name></person-group> (<year>2016</year>) <article-title>A systematic review of the sensitivity and specificity of the toe-brachial index for detecting peripheral artery disease.</article-title><source>Vascular Medicine</source><volume>21</volume>(<issue>4</issue>): <fpage>382</fpage>–<lpage>389</lpage>. <ext-link xlink:href="10.1177/1358863X16645854" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1177/1358863X16645854</ext-link></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Weikert</surname><given-names>C</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>MB</given-names></name><name name-style="western"><surname>Pischon</surname><given-names>T</given-names></name><name name-style="western"><surname>Berger</surname><given-names>K</given-names></name><name name-style="western"><surname>Joost</surname><given-names>HG</given-names></name><name name-style="western"><surname>Häring</surname><given-names>HU</given-names></name><name name-style="western"><surname>Boeing</surname><given-names>H</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>A</given-names></name></person-group> (<year>2008</year>) <article-title>Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke.</article-title><source>Circulation</source><volume>118</volume>(<issue>24</issue>): <fpage>2555</fpage>–<lpage>2562</lpage>. <ext-link xlink:href="10.1161/CIRCULATIONAHA.108.814418" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1161/CIRCULATIONAHA.108.814418</ext-link></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Yilmaz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yonal</surname><given-names>O</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>R</given-names></name><name name-style="western"><surname>Ari</surname><given-names>F</given-names></name><name name-style="western"><surname>Oral</surname><given-names>AY</given-names></name><name name-style="western"><surname>Celikel</surname><given-names>CA</given-names></name><name name-style="western"><surname>Korkmaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Ulukaya</surname><given-names>E</given-names></name><name name-style="western"><surname>Ozdogan</surname><given-names>O</given-names></name><name name-style="western"><surname>Imeryuz</surname><given-names>N</given-names></name><name name-style="western"><surname>Avsar</surname><given-names>E</given-names></name><name name-style="western"><surname>Kalayci</surname><given-names>C</given-names></name></person-group> (<year>2010</year>) Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Annals of Clinical Biochemistry 47(Pt 6): 549–553. <ext-link xlink:href="10.1258/acb.2010.010169" ext-link-type="doi" xlink:type="simple">https://doi.org/10.1258/acb.2010.010169</ext-link></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Zhao</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CG</given-names></name><name name-style="western"><surname>Wu</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YK</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>XF</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name></person-group> (<year>2013</year>) <article-title>Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes.</article-title><source>Biomarkers</source><volume>18</volume>(<issue>2</issue>): <fpage>160</fpage>–<lpage>164</lpage>. <ext-link xlink:href="10.3109/1354750X.2012.762806" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3109/1354750X.2012.762806</ext-link></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name></person-group> (<year>2019</year>) Circulating Fetuin-A and Risk of All-Cause Mortality in Patients With Chronic Kidney Disease: A Systematic Review and MetaAnalysis. Frontiers in Physiology 10: 966. <ext-link xlink:href="10.3389/fphys.2019.00966" ext-link-type="doi" xlink:type="simple">https://doi.org/10.3389/fphys.2019.00966</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
